肾元胶囊联合阿魏酸哌嗪治疗慢性肾炎的临床研究

Clinical study on Shenyuan Capsules combined with piperazine ferulate in treatment of chronic nephritis

目的探讨肾元胶囊联合阿魏酸哌嗪治疗慢性肾炎的临床疗效。方法选取2019年1月—2021年1月在汉中职业技术学院附属医院治疗的116例慢性肾炎患者为研究对象,根据随机数字表法分为对照组(58例)和治疗组(58例)。对照组患者口服阿魏酸哌嗪胶囊,200 mg/次,3次/d。治疗组患者在对照组基础上口服肾元胶囊,5粒/次,3次/d。两组患者均连续治疗30 d。观察两组患者临床疗效,比较治疗前后两组患者临床症状好转时间、肾功能、尿蛋白、血浆白蛋白指标,血清炎性因子白细胞介素6(IL-6)、白细胞介素2(IL-2)、肿瘤坏死因子α(TNF-α)和超敏C反应蛋白(hs-CRP)水平及不良反应情况。结果治疗后,治疗组患者总有效率明显高于对照组(98.28%vs 82.76%,P<0.05)。治疗后,治疗组患者临床症状好转时间均早于对照组(P<0.05)。治疗后,两组血浆尿素氮(BUN)、血浆肌酐(Scr)、24 h尿蛋白明显低于治疗前,而血浆白蛋白(Alb)指标明显升高(P<0.05),且治疗组患者明显好于对照组(P<0.05)。治疗后,两组血清炎性因子IL-6、TNF-α和hs-CRP水平明显下降,而IL-2水平明显升高(P<0.05),且治疗组患者血清炎性因子水平明显好于对照组(P<0.05)。治疗组患者不良反应发生率明显低于对照组(8.62%vs 18.97%,P<0.05)。结论肾元胶囊与阿魏酸哌嗪胶囊联合治疗慢性肾炎效果显著,临床症状好转较快,能有效改善肾脏功能,并降低炎性反应,且药物安全有效。

Objective To investigate the curative effect of Shenyuan Capsules combined with piperazine ferulate in treatment of chronic nephritis. Methods Patients(116 cases) with chronic nephritis in the Affiliated Hospital of Hanzhong Vocational and Technical College from January 2019 to January 2021 were randomly divided into control(58 cases) and treatment(58 cases) groups according to random number table method. Patients in the control group were po administered with Piperazine Ferulate Capsules, 200 mg/time, three times daily. Patients in the treatment group were po administered with Shenyuan Capsules, 5 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, the improvement time of clinical symptoms, renal function, urine protein, albumin indexes, the serum inflammatory factors levels of IL-6, TNF-α, hs-CRP, and IL-2, and the drug adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was significantly higher than that of the control group(98.28% vs 82.76%, P < 0.05). After treatment, the improvement time of clinical symptoms in the treatment group was earlier than that in the control group(P < 0.05). After treatment, the levels of BUN, Scr, and 24-hour urinary protein in two groups were significantly lower than those before treatment, while the index of Alb in the treatment group was significantly higher than that in the control group(P < 0.05), and these indexes in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the serum inflammatory factors levels of IL-6, TNF-α, and hs-CRP in two groups were significantly decreased, while the level of IL-2 were significantly increased, and the level of serum inflammatory factors in the treatment group was significantly better than that in the control group(P < 0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group(8.62% vs 18.97%, P < 0.05). Conclusion The combined treatment of Shenyuan Capsules and Piperazine Ferulate Capsules has a significant effect, can quickly improve clinical symptoms, effectively improve the ability of renal function, and reduce inflammatory reaction, and the drug is safe and effective.